3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Breast Neoplasms
25
Neoplasm Metastasis
6
Ovarian Neoplasms
5
Endometrial Neoplasms
5
Uterine Cervical Neoplasms
3
Triple Negative Breast Neoplasms
3
Prostatic Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms by Site
2
Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Diseases
2
Advanced Breast Cancer
2
Uterine Neoplasms
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Spinocerebellar Degenerations
1
Small Cell Lung Carcinoma
1
Melanoma
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Genital Neoplasms, Female
1
Genetic Diseases, Inborn
1
Fallopian Tube Neoplasms
1
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Interventions
Nivolumab
21
pembrolizumab
19
Ipilimumab
14
Specimen Handling
12
Magnetic Resonance Spectroscopy
7
Opdualag
6
CTLA-4 Antigen
6
relatlimab
5
binimetinib
5
trametinib
4
Paclitaxel
4
dabrafenib
3
Taxes
3
Standard of Care
3
Pemetrexed
3
Introns
3
Interferon alpha-2
3
Gemcitabine
3
Carboplatin
3
Blood Specimen Collection
3
ulixertinib
2
sargramostim
2
lifileucel
2
lenvatinib
2
fludarabine phosphate
2
fludarabine
2
encorafenib
2
capivasertib
2
cabozantinib
2
atezolizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Fulvestrant
×
30 days
×
Clear all
NCT07340619
2026-05-19
EPIBREAST
UNICANCER
Phase 2
Not yet recruiting
51 enrolled